Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...

A study published in Scientific Reports found that cannabidiol (CBD) disrupts lipid metabolism and induces apoptosis in ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

For patients given the wrong diagnosis, the repercussions can be devastating. So if you're not convinced by your doctor's ...

Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, capital ...

AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.

Acrivon Therapeutics, Inc.’s ACRV share price has surged by 17.94%, which has investors questioning if this is right time to ...

The Pill prevents pregnancy -- and maybe ovarian cancer, too, a new study suggests.Women who’ve ever used the contra ...